The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.
GreenMark Biomedical Inc. is a healthcare company focused on developing minimally invasive technologies utilizing biopolymer nanoparticles derived from natural starch. Founded in 2016 and based in East Lansing, Michigan, with a laboratory in Ann Arbor, the company aims to enhance diagnostic and treatment capabilities in dentistry and oncology. GreenMark offers a mouth rinse product that highlights cavities and early-stage lesions, allowing dentists to accurately assess dental issues using standard dental curing lamps. Additionally, the company is working on medical applications that target anti-cancer drug delivery, facilitating site-specific treatments. Through its innovative approach, GreenMark Biomedical seeks to provide effective health-based solutions that improve patient care.
Sonomotion
Grant in 2025
SonoMotion Inc. is a medical device company focused on developing non-invasive solutions for kidney stone disease. Founded in 2012 and based in San Mateo, California, the company offers innovative products such as Break Wave, which safely fragments large kidney stones, and Stone Clear, which aids in clearing the resulting stone fragments within 15 minutes in an office setting, without the need for general anesthesia or X-ray radiation. SonoMotion is actively involved in advancing its technology, with a stone repositioning solution currently undergoing clinical trials and a second-generation stone-breaking technology in development. The company's mission is to provide effective and cost-efficient treatments for kidney stone patients.
LUCID DIAGNOSTICS
Grant in 2025
Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.
Myosin Therapeutics
Seed Round in 2025
Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company focuses on creating novel drugs that target cellular motor proteins, which are essential molecular machines that convert energy into mechanical work within cells. This unique approach enables the potential treatment of various disease states, including cancer. By harnessing the capabilities of these motor proteins, Myosin Therapeutics aims to advance therapeutic options and improve patient outcomes in challenging medical areas.
UCLA Health System
Grant in 2025
Comprised of Ronald Reagan UCLA Medical Center, UCLA Medical Center, Santa Monica; Resnick Neuropsychiatric Hospital at UCLA, Mattel Children's Hospital UCLA, and the UCLA Medical Group with its wide-reaching system of primary-care and specialty-care offices throughout the region, UCLA Health System is among the most comprehensive and advanced healthcare systems in the world.
Neuronoff
Grant in 2025
Neuronoff, a medical device company, is focused on the development of the Injectrode™, a novel injectable metal electrode, which is deployed via a small needle for manufacturing the neuromodulation interface inside the body on a variety of anatomical targets.
IVOS Medical
Grant in 2025
IVOS Medical is an innovative medical device company focused on advancing airway management technology.
Vast Therapeutics
Grant in 2025
Vast Therapeutics is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Founded in 2017 and originally known as Novoclem Therapeutics, the company aims to address chronic infections prevalent among the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing innovative therapeutic solutions for individuals facing these challenging health conditions.
Arkansas Children's Research Institute
Grant in 2025
Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.
Feinstein Institute for Medical Research
Grant in 2025
Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.
University of Louisville
Grant in 2025
The University of Louisville is a public research university that offers a wide range of undergraduate and graduate programs across various disciplines. It is particularly known for its contributions to health, engineering, and the humanities. The university actively engages with community partners to enhance its academic and research initiatives, thereby creating a significant impact on education, healthcare, and research industries. Additionally, the University of Louisville School of Dentistry serves as a specialized institute within the university, focusing on dental education and training.
University of Arkansas for Medical Sciences
Grant in 2025
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
Elimu Informatics
Grant in 2024
Elimu Informatics is a developer of cloud-based clinical decision support software designed for healthcare professionals. The company's expertise lies in clinical decision support, semantic normalization, and workflow integration. By focusing on these areas, Elimu Informatics aims to enhance the quality of care, improve patient experiences, and increase usability for healthcare providers. Their solutions allow healthcare professionals to access advanced tools and insights without the burden of additional development costs or lengthy implementation timelines.
BMI OrganBank
Grant in 2024
BMI OrganBank specializes in the development of advanced medical devices and perfusion technology aimed at enhancing the preservation of organs and tissues for transplantation. By collaborating with academic institutions, the company seeks to expand the potential of organ transplantation and improve patient outcomes. Its focus includes innovative solutions that could significantly transform kidney transplantation and other organ preservation methods, ultimately benefiting thousands of patients in need of transplants. The company’s efforts also extend to developing technologies for organ preservation, such as lung ventilators and ex vivo tissue perfusion, which enable healthcare providers to deliver better medical care.
Mount Sinai Health System
Grant in 2024
Mount Sinai Health System is an integrated healthcare system based in New York, providing exceptional medical care to local and global communities. Established in 2013 through the merger of Mount Sinai Medical Center and Continuum Health Partners, it encompasses the Icahn School of Medicine and operates seven hospital campuses throughout the New York metropolitan area. The system is recognized for its excellence in research, patient care, and education across various specialties. It features a vast network of over 7,000 primary and specialty care physicians, as well as more than 45 ambulatory practices and 12 minority-owned free-standing ambulatory surgery centers. Mount Sinai is committed to improving healthcare quality and accessibility, focusing on compassionate patient experiences and the development of strong relationships between staff and patients. Additionally, its venture capital arm, Mount Sinai Ventures, invests in healthcare startups, further enhancing its capacity to innovate and respond to the diverse health needs of the populations it serves.
ReShape Medical
Grant in 2024
ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.
Brixton Biosciences
Grant in 2024
Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for chronic and acute pain management. The company aims to address significant unmet needs in this area, which has traditionally relied on systemic medications. Its flagship product, Neural Ice™, is a drug-free injectable treatment designed to induce reversible inhibition of nerves, offering a non-addictive, locally targeted solution. This therapy provides patients with extended pain relief lasting from thirty to sixty days following a single injection, representing a significant advancement over current pain management methods.
YoungHeartValve
Grant in 2024
Young Heart Valve is a Polymeric, Hyaluronan-Enhanced Transcatheter Aortic Valves which were developed by engineers with inspiration from nature. The future of heart valve intervention is being altered by Young Heart Valve. Animal tissue is no longer required thanks to Young Heart Valve. Hyaluronan is included into the leaflets of Young Heart Valve's RejuvenateTM TAVR device, forming a biomolecular interpenetrated network that has been shown to be resistant to calcification and thrombosis.
ATCC
Grant in 2024
ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.
Pip Care
Grant in 2024
Pip Care is a healthcare company that specializes in enhancing the surgical journey through a personalized platform designed for health systems. The company collaborates with these systems to streamline the perioperative care process, supporting care teams and patients from pre-surgery preparation to post-operative recovery. Pip Care offers a dedicated app that empowers patients by providing certified health coaches who create individualized care plans, including daily tasks and tailored advice, helping them manage appointments and feel prepared for their surgeries. By focusing on the digitization and automation of perioperative workflows, Pip Care aims to improve surgical outcomes for patients while also enhancing the financial performance of healthcare providers.
Arkansas Children's Research Institute
Grant in 2024
Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.
Allyx Therapeutics
Grant in 2024
Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.
CardieX
Grant in 2024
CardieX Limited is a global health technology company specializing in cardiovascular health management. Founded in 1994 and headquartered in Sydney, Australia, the company designs, manufactures, and markets medical devices aimed at measuring patient risk for hypertension, cardiovascular disease, and other vascular disorders. Its product offerings include devices that utilize patented SphygmoCor technology to assess arterial stiffness and central blood pressure waveforms. Additionally, CardieX develops the Arty platform, which provides physiological and health analytics for wearable devices. The company also offers TeleHealth Services, connecting patients with health coaches through digital and mobile tools. CardieX's solutions are provided to hospitals, clinics, research institutions, and pharmaceutical companies globally. The company has strategic partnerships, including a collaboration with Blumio Inc. for developing wearable sensors and a joint development agreement with inHealth for hypertension and cardiovascular programs. CardieX was previously known as AtCor Medical Holdings Limited until its name change in June 2018.
University of Michigan
Grant in 2024
The University of Michigan, one of the largest universities in the Midwest, offers a diverse array of academic programs that attract over 40,000 undergraduate, graduate, and professional students. Its renowned schools include the Stephen Ross School of Business, the College of Engineering, and prominent law and medical schools. The university also has a vibrant arts scene, highlighted by its Musical Theatre program and the annual Ann Arbor Film Festival, which draws filmmakers globally. In addition to its educational endeavors, the University of Michigan actively manages a significant endowment, investing in alternative assets such as private equity, real estate, and infrastructure to support its mission and enhance its resources. The institution consistently ranks highly in national assessments, reflecting its commitment to academic excellence and innovation.
Southern California University of Health Sciences
Grant in 2024
Southern California University of Health Sciences has been a leader in educating students to be competent and caring integrative healthcare practitioners for over 100 years. SCU has a history of providing the highest levels of patient care and has gained a reputation for excellence in an evidenceinformed curriculum. SCU is the best place to prepare for a successful, significant, and rewarding career.
Rosalind Franklin University of Medicine and Science
Grant in 2024
Rosalind Franklin University of Medicine and Science, established in 1912, is a North Chicago, Illinois-based institution dedicated to educating future health science leaders. It comprises five schools offering degrees such as Doctor of Medicine, Doctor of Podiatric Medicine, Nurse Anesthesia, Physical Therapy, and Physician's Assistant. The university fosters research and provides opportunities for students to engage in it, both on campus and through partnerships with nearby institutions. It aims to enrich students' lives professionally, mentally, and socially through various organizations and activities. Admission requirements vary by school but generally seek students with a strong scientific background and leadership skills. The university offers financial aid to eligible students who demonstrate need.
CytoAgents
Grant in 2024
CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.
Oklahoma Medical Research Foundation
Grant in 2024
The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.
Amissa Health
Grant in 2024
Amissa develops mobile and wearable application solutions aimed at alleviating the challenges of Alzheimer's care. The company’s technology empowers caregivers by allowing them to geo-fence and locate loved ones who may wander, remotely monitor their activity and health, and predict behaviors associated with Alzheimer's. In addition to these features, Amissa offers wearable biosensors integrated with a cloud-based data platform that collects biometric data on activity levels, sleep patterns, and physiological changes. This comprehensive approach not only aids caregivers in monitoring patients but also provides valuable insights for researchers seeking to understand disease progression, ultimately enhancing the quality of life for individuals with dementia and related disorders.
Resvita Bio
Grant in 2024
Resvita Bio is engaged in the development and manufacturing of engineered probiotics aimed at treating skin-related diseases, including chronic conditions and cancer. The company focuses on creating a versatile skin microbial platform utilizing synthetic biology and metabolic engineering. This innovative approach allows for the continuous delivery of therapies that alleviate inflammation, promote tissue regeneration, and eliminate harmful bacteria. By leveraging this technology, Resvita Bio aims to offer faster and more efficient treatment alternatives for individuals suffering from chronic skin diseases.
Cenna Biosciences
Grant in 2024
Cenna Biosciences focuses on the discovery and development of innovative drugs aimed at preventing and treating Alzheimer's disease. The company utilizes a proprietary technology that targets the underlying cause of the disease, specifically addressing the harmful accumulation of beta-amyloid (Aß) in the brains of affected individuals. Cenna has identified a novel target and is in the process of developing several lead peptide compounds as potential disease-modifying treatments for Alzheimer's.
Tiziana Life Sciences
Grant in 2024
Tiziana Life Sciences is a clinical-stage biotechnology company based in London, UK, focused on discovering and developing novel therapeutic molecules for oncology and immunology. The company's product pipeline includes Foralumab, a human anti-CD3 monoclonal antibody aimed at treating autoimmune and inflammatory diseases such as graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently undergoing phase II clinical trials for epithelial thymic carcinoma. Additionally, Tiziana is developing Anti IL-6r, a monoclonal antibody targeting interleukin-6 for severe COVID-19 cases, and StemPrintER, a multi-gene signature assay for estrogen-receptor positive breast cancer patients. Founded in 2013, Tiziana Life Sciences is dedicated to advancing innovative therapies for serious diseases, including neurodegenerative disorders and lung diseases.
TransCode Therapeutics
Grant in 2024
TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.
Subtle Medical
Grant in 2024
Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.
Precision Epigenomics
Grant in 2024
Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.
EVOQ Therapeutics
Grant in 2024
Evoq Therapeutics is a company specializing in cancer immunotherapy and the treatment of autoimmune diseases. It employs a proprietary technology platform that features a NanoDisc, designed to deliver disease-specific immune modulators effectively. This innovative approach aims to restore immune tolerance, allowing the body to better manage conditions such as celiac disease, type one diabetes, lupus, pemphigus, Graves' disease, and rheumatoid arthritis. By targeting these diseases through its novel nanodisc-based therapy, Evoq Therapeutics seeks to improve the lives of individuals affected by autoimmune disorders and enhance the overall efficacy of treatment strategies in various pre-clinical models.
Penderia Technologies
Grant in 2024
Penderia Technologies is a medical device company focused on innovative orthopedic solutions. It develops implantable, battery-less sensors for monitoring injury and healing progress in real-time, enabling personalized rehabilitation therapies.
University of Arkansas for Medical Sciences
Grant in 2024
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
Immunovia
Grant in 2024
Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. Utilizing its proprietary IMMray platform, which is based on antibody microarray analysis, Immunovia develops and commercializes innovative diagnostic tools. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests, collaborating with medical institutions and research centers worldwide. By concentrating on early detection, Immunovia aims to enhance the treatment and management of pancreatic cancer, thereby improving patient survival rates. The technology developed by Immunovia could also facilitate early detection strategies for other cancers and autoimmune diseases in the future.
Cortechs.ai
Grant in 2024
Cortechs.ai is a developer of brain image analysis software that enhances clinical insight through quantitative imaging. The company's innovative solutions are utilized by neurologists and radiologists in numerous clinics and research centers globally. Its software provides a practical and cost-effective approach to quantifying brain structures, aiding medical professionals in the evaluation of various neurological conditions, including Alzheimer's disease, multiple sclerosis, epilepsy, and traumatic brain injury. Through its advanced imaging technology, Cortechs.ai aims to improve diagnostic accuracy and treatment outcomes in the field of neurology.
Anebulo Pharmaceuticals
Grant in 2024
Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials have demonstrated that ANEB-001 is rapidly absorbed and well-tolerated by patients. Additionally, it has been observed to induce weight loss, an effect linked to its action as a central cannabinoid receptor type 1 antagonist. The company aims to address the wide range of symptoms associated with cannabinoid overdose, which can include profound sedation, anxiety, panic, and psychosis with hallucinations.
Arkansas Children's Research Institute
Grant in 2024
Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.
Weill Cornell Medicine
Grant in 2024
Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.
Metabolon
Grant in 2024
Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.
Matter Bio
Grant in 2024
Matter Bio is a biotechnology company dedicated to preserving genome integrity and enhancing longevity through the preservation of DNA information. The company aims to address the critical issue of information loss in the genome by assembling a team of expert scientists and executives. By focusing on mutation reversal, Matter Bio seeks to empower patients with the potential to improve their health and extend their lifespan. Through its innovative research services, the company strives to advance the understanding and application of genetic preservation techniques.
Nanopath
Grant in 2024
Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.
Phenomix Sciences
Grant in 2024
Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.
Arkansas Children's Research Institute
Grant in 2024
Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.
Selsym
Grant in 2024
Selsym Biotech is a biotechnology company focused on developing innovative therapies aimed at controlling bleeding in trauma and surgical situations. The company's flagship product, Hemostatic Healing Hydrogels (H3), offers a novel solution to address critical challenges in hemorrhage control, particularly in light of ongoing platelet supply shortages and limitations related to shelf life. By providing effective platelet-mimetic therapies, Selsym Biotech seeks to revolutionize the management of uncontrolled bleeding, enhancing outcomes for patients in emergency and surgical settings.
University of Arkansas for Medical Sciences
Grant in 2024
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
Lamassu Pharma
Grant in 2024
Lamassu Pharma is a biotech startup dedicated to addressing the significant unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown promising preclinical results in significantly reducing both mortality and morbidity associated with this condition. This therapeutic candidate, developed by leading scientists at Mayo Clinic, aims to improve medical outcomes for patients suffering from acute pancreatitis. Lamassu Pharma is currently advancing the development of this compound through safety testing, preparing for future clinical trials with the ultimate goal of saving lives and enhancing treatment options for those affected by this serious disease.
Springbok Analytics
Grant in 2024
Springbok Analytics offers an AI-powered software platform that transforms MRIs into three-dimensional analyses of muscle to enable true precision. Springbok Analytics' advanced imaging technology identifies and measures each individual muscle, providing data to scientists, physical therapists, athletic trainers, and physicians to evaluate muscle function in relation to performance and injury management. The technology has numerous applications, including injury management, performance enhancement, and the treatment of musculoskeletal conditions.
Phase
Grant in 2024
Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
Maxim Biotech
Grant in 2024
Maxim Biotech provides vitro diagnostic testing development and testing solutions.
Perspective Therapeutics
Grant in 2024
Perspective Therapeutics is a medical technology and radiopharmaceutical company focused on innovative cancer treatment solutions. The company employs a proprietary technology that uses the alpha-emitting isotope 212Pb combined with specialized targeting peptides to deliver targeted radiation directly to cancer cells. This approach aims to enhance the effectiveness of treatments while minimizing side effects, reflecting the company's commitment to personalized and precise medicine in addressing patients' medical needs.
AcuraStem
Grant in 2024
AcuraStem Inc is a biotechnology company, founded in 2016 and based in Monrovia, California, that focuses on developing a precision medicine platform aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The company utilizes complex cellular models derived from ALS patients to evaluate disease progression and test existing FDA-approved therapeutics and their combinations. By employing advanced cellular reprogramming and artificial intelligence technologies, AcuraStem seeks to transform the standard of care for neurodegenerative diseases, enabling drug discovery companies to assess their therapeutic candidates more effectively. The team comprises experts, including PhDs, professors, and experienced professionals from the pharmaceutical industry, all dedicated to finding innovative treatments for this challenging health issue.
University of Arkansas for Medical Sciences
Grant in 2024
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
University of Arkansas for Medical Sciences
Grant in 2023
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
The Stark Neurosciences Research Institute
Grant in 2023
The Stark Neurosciences Research Institute is dedicated to improving outcomes for persons suffering from disorders of the nervous system.
Hillhurst Biopharmaceuticals
Grant in 2023
Hillhurst Biopharmaceuticals specializes in developing innovative, liquid therapeutic gases for treating sickle cell disease. Their core technology enables the precise, oral delivery of low-dose carbon monoxide, targeting a protective cellular mechanism to reduce inflammation, prevent cell death, and inhibit hemoglobin polymerization. This approach addresses challenges associated with traditional inhaled gas therapies, such as caregiver exposure and imprecise dosing, ensuring accurate and safe administration.
Rivanna
Grant in 2023
Rivanna Medical, LLC is a medical technology company based in Charlottesville, Virginia, founded in 2010. The company focuses on developing and commercializing innovative ultrasound-based systems aimed at enhancing the application of spinal and epidural anesthesia through advanced 3D navigation of the lumbar spine. Its flagship product, Accuro, not only facilitates precise anesthesia delivery but also supports various diagnostic imaging needs, including musculoskeletal and abdominal anatomies. Rivanna Medical is committed to improving patient outcomes and lowering healthcare costs while minimizing patient exposure to radiation commonly associated with X-ray-based imaging techniques.
L2P Research
Grant in 2023
L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company focuses on preclinical and toxicology services, utilizing proprietary orthotopic and metastatic tumor models. L2P Research Labs offers a range of advanced technologies, including quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans, as well as focal radiation. These capabilities allow researchers to access a complete suite of research services tailored to their needs, facilitating the advancement of scientific studies and drug development.
Rational Vaccines
Grant in 2023
Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to combat herpes simplex virus and its related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutic and prophylactic vaccine candidates that aim to reduce the transmission of the herpes virus and effectively manage symptoms associated with its reactivation. By harnessing rational engineering techniques, Rational Vaccines seeks to revolutionize the treatment, prevention, and diagnosis of herpes infections, ultimately improving the quality of life for those affected by these conditions.
SINTX Technologies
Grant in 2023
SINTX Technologies, Inc. is a biomaterial company specializing in the research, development, manufacturing, and commercialization of medical implant products made from silicon nitride. Founded in 1996 and headquartered in Salt Lake City, Utah, SINTX offers a range of ceramic-based biomaterial solutions applicable in various medical and industrial fields. The company primarily focuses on producing spinal implant products, marketed under the Valeo brand, which are used in cervical and thoracolumbar surgeries. SINTX operates an ISO 13485 certified manufacturing facility and collaborates with external partners, providing custom manufacturing and development of silicon nitride ceramics for both medical and non-medical applications. Its products are recognized for their biocompatibility, bioactivity, and excellent bone affinity, and have been successfully implanted in patients across the United States, Europe, Brazil, and Taiwan.
Clene Nanomedicine
Grant in 2023
Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.
Actinium Pharmaceuticals
Grant in 2023
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing radiotherapies for patients with cancer. The company's lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as a conditioning agent for patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to bone marrow transplantation. Another key candidate, Actimab-A, is in Phase II trials targeting newly diagnosed acute myeloid leukemia in patients aged 60 and older. Additionally, Actinium is developing Actimab-M for penta-refractory multiple myeloma, currently in Phase I trials. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. Actinium also collaborates with Astellas Pharma to advance its technology. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in hematology through innovative therapeutic approaches.
Omniose
Grant in 2023
Omniose is an early-stage biotechnology company focused on developing advanced conjugate vaccines to combat infectious diseases. The company specializes in pneumococcal conjugate vaccines, aiming to offer broader protection against various bacterial strains. Utilizing proprietary bioconjugation technology, Omniose's approach eliminates reliance on synthetic chemistry techniques, allowing for the generation of polysaccharide-protein conjugate-based vaccines targeting multiple pathogens, including respiratory infections caused by Streptococcus pneumoniae. This innovative platform enhances the ability of healthcare professionals to effectively treat patients by providing more comprehensive vaccine options.
University of Minnesota Medical School
Grant in 2023
University of Minnesota Medical School educates students, provides patient care, and performs biomedical and clinical research. UMN Medical School offers medical, graduate, and undergraduate degree programs, as well as continuing professional development. The Medical School has two campuses based in the Twin Cities and Duluth, Minnesota. The Twin Cities campus is an interdisciplinary research center. The Duluth campus educates 130 first and second-year medical students committed to practicing in rural or American Indian communities.
Golden Helix
Grant in 2023
Golden Helix specializes in bioinformatics solutions that enhance life science research and translational medicine. With over 20 years of experience, the company offers innovative technologies and analytic services designed to help scientists and healthcare professionals interpret vast amounts of genomic data generated from microarrays and next-generation sequencing. Their cloud-based software efficiently manages, analyzes, and visualizes complex genomic and phenotypic datasets. By streamlining the processes of annotating and filtering variants, Golden Helix empowers biologists and researchers to conduct sophisticated analyses and visualizations independently, reducing the reliance on bioinformatics experts.
South Rampart Pharma
Grant in 2023
South Rampart Pharma is a clinical-stage life science company dedicated to developing safe and effective pain relief alternatives. The company focuses on synthesizing and characterizing new non-opioid and non-liver toxic molecules that target pain signaling pathways in the brain's periaqueductal grey (PAG) region. Its lead candidate, SRP-001, has received U.S. FDA Fast Track designation for acute pain treatment. This candidate aims to influence pain-related genes through various biological pathways, including endocannabinoid signaling and mechanical nociception, providing a promising solution to mitigate the risks associated with traditional pain medications, particularly their potential for abuse.
Strykagen
Grant in 2023
Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.
Burst Diagnostics
Grant in 2023
Burst Diagnostics specializes in at-home and point-of-care medical testing through its innovative rapid antigen diagnostics platform. The company has developed a paper-based testing system that offers the sensitivity and specificity comparable to traditional laboratory methods, such as ELISA. This technology allows for easy deployment from laboratories to home use, facilitating efficient testing for a range of conditions, including SARS-CoV-2. The user-friendly design resembles a lateral flow assay, making it accessible to both medical professionals and patients. Burst Diagnostics aims to revolutionize the diagnostic landscape by providing rapid, reliable testing solutions directly in the hands of users.
Boston University Chobanian & Avedisian School of Medicine
Grant in 2023
Boston University Chobanian & Avedisian School of Medicine is a school of medicine focus on treating disadvantaged and underserved populations.
ReShape Medical
Grant in 2023
ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.
Glyphic Biotechnologies
Grant in 2023
Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.
Glyphic Biotechnologies
Grant in 2023
Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.
Subtle Medical
Grant in 2023
Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.
Greenstone Biosciences
Grant in 2023
Greenstone Biosciences is a drug discovery platform focused on accelerating the development of effective therapies for patients with urgent unmet medical needs. The company leverages advanced technologies, including artificial intelligence and human-induced pluripotent stem cells, to transform the traditional drug discovery process. By integrating these innovative approaches, Greenstone aims to streamline what is typically a slow and high-failure endeavor into a more rapid and efficient system, ultimately delivering safe and effective therapeutics to patients.
Spinogenix
Grant in 2023
Spinogenix, Inc., founded in 2016 and based in San Diego, California, specializes in developing neurorestorative therapeutics aimed at addressing neurodegenerative and psychiatric diseases. The company focuses on regenerating synapses to reverse declines in cognitive and motor function, seeking to create transformative treatments for conditions characterized by synaptic loss and dysfunction. Spinogenix aims to offer innovative drugs that restore brain connections affected by neurodegenerative diseases and brain injuries. Their approach involves directly modulating synaptic proteins, with the potential for their therapeutics to be used as standalone treatments or in combination with other therapies targeting specific degenerative processes.
Daxor
Grant in 2023
Daxor Corporation is a medical device and biotechnology firm based in New York, specializing in blood volume measurement. The company developed the BVA-100 Blood Volume Analyzer, which is the first FDA-approved instrument designed to provide rapid and accurate measurement of a patient's true blood volume. This innovative device is utilized in diagnosing and treating various medical conditions, including congestive heart failure, hypertension, and anemia, among others. Daxor also offers additional services such as semen banking, blood storage, and laboratory testing. The company has established a cooperative research agreement with the Uniformed Services University of the Health Sciences to study the efficacy of the BVA-100 in assessing blood volume in traumatic injury contexts. Founded in 1970 and originally known as Idant Corporation, Daxor Corporation has positioned itself at the forefront of medical instrumentation technology.
Buck Institute
Grant in 2023
The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.
National Disease Research Interchange
Grant in 2023
National Disease Research Interchange is the source of human tissues, cells and organs for scientific research. Top 250k Enrichment Emp Range Freshness 2024 - Not Found
Boston Immune Technologies & Therapeutics
Grant in 2023
Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.
PediaMetrix
Grant in 2023
PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.
Curi Bio
Grant in 2023
Curi Bio is a biotechnology company dedicated to enhancing drug discovery and development through innovative technologies that leverage human stem cells, systems biology, and data analytics. The company aims to streamline the identification and development of new medicines by providing advanced biosystem platforms that integrate human cells and data. Curi Bio's technology offers a range of products designed for cell and tissue engineering, drug discovery, disease modeling, and fundamental cell biology research. By enabling in vivo maturation and alignment of various cell types, the company allows drug developers to conduct more accurate safety and efficacy tests on new drug candidates, ultimately fostering the advancement of next-generation human medicines.
Talus Bio
Grant in 2023
Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.
University of Utah
Grant in 2023
The University of Utah, located in Salt Lake City, is the state's leading public university and the sole institution in Utah offering a medical school. It provides a diverse range of academic programs, featuring over 100 undergraduate majors in fields such as business, engineering, and health careers, as well as more than 90 graduate degrees. In addition to its medical school, the university also includes schools of law and pharmacy. The University of Utah promotes an active student life, hosting over 400 clubs and organizations, alongside recreational programs and cultural events. Admission to the undergraduate programs requires an application, along with academic transcripts and standardized test scores, with a minimum GPA of 2.6 and typical ACT/SAT scores around 18 and 860, respectively. Financial aid is available based on need, and students are encouraged to complete the FAFSA to determine their eligibility for various forms of assistance, including scholarships and loans.
Morehouse School of Medicine Endowment
Grant in 2023
Morehouse School of Medicine, located in Atlanta, Georgia, is a historically Black college and university (HBCU) dedicated to training healthcare professionals, with a special emphasis on minority students. The institution offers a medical degree program along with master’s degrees in various fields, including Public Health and Biomedical Sciences. Medical students can specialize in areas such as Family Medicine, Internal Medicine, Obstetrics and Gynecology, Pediatrics, Psychiatry, and Surgery, completing clinical assignments at affiliated hospitals. The school is also engaged in research, focusing on cardiovascular studies, neuroscience, and health disparities. To support its mission, Morehouse manages an endowment fund, the earnings of which are utilized for scholarships, research funding, and academic programs. Admissions requirements vary by program, and the school provides scholarships aimed at supporting disadvantaged students, alongside academic and merit-based financial aid.
University of Oklahoma - Health Sciences Center
Grant in 2023
University of Oklahoma Health Sciences Center, as a comprehensive academic health center, is to educate students, residents, and other trainees in professional and graduate programs to become Oklahoma’s future team of healthcare leaders, clinicians, researchers, and educators; to advance distinctive basic, translational, clinical, and population research; to innovate and commercialize discoveries; and to deliver exceptional patient care across the full breadth of adult, women’s, and children’s specialties.
Medical College of Wisconsin
Grant in 2023
The Medical College of Wisconsin, established in 1893 and located in Milwaukee, is dedicated to advancing education and research in the biomedical and health sciences. It offers a range of graduate programs, including bioethics, healthcare technologies management, and pharmacology. The institution employs a unique Discovery Curriculum that emphasizes personalized learning experiences, combining classroom instruction with clinical practice under the guidance of experienced faculty. The college is also home to the Student Teaching Assessment Resource Center, where students and medical professionals can hone their clinical skills using advanced medical simulators. The college's endowment fund, supported by donations and alumni gifts, provides essential funding for research, departmental initiatives, and scholarships. The Medical College of Wisconsin aims to improve community health and cultivate the next generation of healthcare professionals, while also offering financial aid options to students.
Inherent Biosciences
Grant in 2023
Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.
Glyphic Biotechnologies
Grant in 2023
Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.
CivaTech Oncology
Grant in 2023
Civatech Oncology is a medical device company based in Durham, North Carolina, that specializes in developing polymer-based devices for the treatment of cancer through localized low-dose-rate radiation. Founded in 2006, the company focuses on creating devices tailored for specific tumor types, utilizing its patented technology to manufacture them in various shapes and formats. Its flagship product, the CivaString, has received FDA 510k clearance for the treatment of any solid tumor. Civatech's innovative approach aims to enhance the efficacy of brachytherapy for early-stage cancers by reducing procedure times, ensuring uniform dose distribution, and minimizing patient trauma.
FesariusTherapeutics
Grant in 2023
Fesarius Therapeutics is a biotechnology company focused on developing modified skin replacement products through innovative tissue engineering technology. The company utilizes a proprietary method involving microspheres embedded in a collagen hydrogel, which enhances the interfaces that facilitate cell invasion into the scaffold. This approach aims to create engineered tissue products that support surgical repair of soft tissue defects, with potential applications in pelvic health, chronic wounds, and aesthetic reconstruction. By prioritizing cost-effective solutions, Fesarius Therapeutics seeks to enable patients to recover from trauma, burns, or infections effectively.
Access to Advanced Health Institute
Grant in 2023
Access to Advanced Health Institute is a nonprofit biotech research institute that brings together specialists, technologies, and platforms to offer accessible goods and solutions for leveraging the immune system to alleviate disease.
MaineHealth
Grant in 2023
MaineHealth is a not-for-profit family of leading high-quality providers and other healthcare organizations working together so our communities are the healthiest in America. Ranked among the nation's top 100 integrated healthcare delivery networks, MaineHealth member organizations include Maine Medical Center, Franklin Community Health Network, LincolnHealth, Maine Behavioral Healthcare,
EndoTheia
Grant in 2023
EndoTheia is a medical equipment manufacturing company specializing in the development of advanced flexible endoscopic devices. The firm's technology incorporates micro-machined smart materials to produce highly dexterous manipulators that operate at millimeter and sub-millimeter scales. This innovation aims to enhance therapeutic outcomes for healthcare professionals conducting complex flexible endoscopic procedures. Through its focus on next-generation medical technology, EndoTheia seeks to improve the efficacy and precision of endoscopic interventions in various clinical settings.
University of Arkansas for Medical Sciences
Grant in 2023
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
Advent Therapeutics
Grant in 2023
Advent Therapeutics is a pharmaceutical company based in Lumberville, Pennsylvania, dedicated to developing therapies for micro-orphan applications, specifically targeting serious unmet medical needs in neonatal and pediatric populations. The company focuses on legacy drugs aimed at treating disorders in newborn infants, particularly those in intensive care units. By creating prenatal, neonatal, and pediatric medications, Advent Therapeutics enables healthcare professionals to provide advanced care for vulnerable patients, addressing critical gaps in existing treatment options for this underserved demographic.
Caeregen Therapeutics
Grant in 2023
Caeregen Therapeutics focuses on the development of innovative pharmacological therapies aimed at healing neurosensory diseases. The company’s primary goal is to repair, restore, and protect damaged neurosensory tissues by reactivating key biological pathways and signaling mechanisms associated with healthy cellular and tissue development. This approach enables the potential treatment of conditions such as retinal-related vision loss, providing patients with new options for recovery and improved quality of life. Through its commitment to regenerative medicine, Caeregen Therapeutics seeks to advance therapeutic solutions that address significant unmet medical needs in the field of neurosensory health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.